RAIN THERAPEUTICSDL-,001

Loading quotes...

Forecast

Buy	4
Hold	8
Sell	0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, RAIN THERAPEUTICSDL-,001 had revenue of €0 and net profit of -€2.84m

(EUR)	June 2026	YoY
Revenue	0	-
Gross profit	-11.63k	-
Net profit	-2.84m	251.92%
EBITDA	-2.56m	229.32%

Fundamentals

Metric	Value
Market capitalization	€4.5m
Number of shares	9.98m
52-week high/low	€7.64 - €0.45
Dividends	No
Beta	-0.22
P/E ratio	-0.33
PEG ratio	0.01
P/B ratio	-0.32
P/S ratio	478.22

Company profile

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.